Search Results for “cancer” – Page 159 – media

Pfizer and Genentech Duke it Out in Court Over Herceptin Biosimilar Patents

On Friday, November 17, Genentech, a Roche company, sued Pfizer in a federal court in Wilmington, Delaware, over Pfizer’s biosimilar for Genentech’s Herceptin. Genentech is claiming that Pfizer’s proposed biosimilar infringes 40 of its patents. Genentech also is demanding compensation for lost sales if Pfizer launches its copycat version before the Herceptin patents expire.
- Source: Biospace
- 640
- November 24, 2017
biosimilar Company Insight FDA Genentech herceptin Pfizer Roche
US FDA grants Breakthrough Therapy Designation for Roche’s Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC

The latest BTD was granted for the treatment of adult patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have not received prior treatment with an ALK inhibitor.
- Source: Roche
- 554
- November 23, 2017
anaplastic lymphoma kinase Company Insight FDA non-small cell lung cancer Roche
China makes use of AI for healthcare

An estimated 300 million Chinese people are smokers. China has also a serious issue with hazardous air pollution. Here concentrations of small, breathable particles (PM2.5) invariably exceeding 300 micrograms per cubic meter in the industrialized northern regions.
- Source: digitaljournal
- 645
- November 23, 2017
Artificial Intelligence China healthcare lung cancer
Stanford, NCI Researchers Discover New CAR-T Target With Early Study Data

Researchers at Stanford University School of Medicine with the National Cancer Institute (NCI) have identified another cancer-surface molecule, CD22, and begun trials on B-cell acute lymphoblastic leukemia (ALL) patients using an immuno-oncology approach similar to CAR-T. In the Phase I trial, 15 of the 21 patients who had previously relapsed or did not respond to anti-CD19 CAR-T, were treated with an anti-CD22 CAR-T therapy. Ten of the 15 patients had already received treatment for CD19-targeted treatment.
- Source: biospace
- 567
- November 22, 2017
cancer CAR–T immuno-oncology Researches
NHS England consults on simplifying research processes

NHS England says it is planning to accelerate the NHS’ national research strategy, “cutting bureaucracy and speeding up access to new and innovative treatments”.
- Source: Pharmatimes
- 450
- November 22, 2017
NHS polices
FDA OKs Genentech’s Gazyva for Untreated Follicular Lymphoma

Twice on Thursday, Genentech, scored two approvals from the U.S. Food and Drug Administration(FDA) – a new medicine for hemophilia and an expansion for its cancer drug Gazyva.
- Source: Biospace
- 589
- November 21, 2017
cancer FDA hemophilia lymphoma New Approvals
For the First Time, a Robot Passed a Medical Licensing Exam

Experts generally agree that, before we might consider artificial intelligence (AI) to be truly intelligent —that is, on a level on par with human cognition— AI agents have to pass a number of tests. And while this is still a work in progress, AIs have been busy passing other kinds of tests.
- Source: futurism
- 490
- November 21, 2017
Artificial Intelligence
Cue Biopharma Announces Strategic Research Collaboration and License Agreement with Merck

Biopharma™, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, announced a strategic research collaboration and license agreement with Merck, known as MSD outside of the United States and Canada.
- Source: biotech-365
- 526
- November 20, 2017
autoimmune immunotherapy Market Views
Pfizer Receives FDA Approval for SUTENT® (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients

Pfizer Inc. (PFE) announced that the U.S. Food and Drug Administration(FDA) has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (surgical removal of the cancerous kidney). The approval was based on results from the S-TRAC trial that demonstrated a significant reduction in the risk of a disease-free survival (DFS) event (defined as the interval between randomization and tumor recurrence, or secondary primary cancer or death from any cause) for patients at high risk of RCC recurrence who received SUTENT compared to placebo in the adjuvant setting.
- Source: finance.yahoo
- 489
- November 20, 2017
DFS FDA nephrectomy RCC SUTENT
Ddu College-China’s Import and Export Market Report of Respiratory System Drugs

Respiratory system drugs is a term used to describe a wide variety of medicines used to relieve, treat, or prevent respiratory diseases such as asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), or pneumonia. Today, Ddu, the leading global pharmaceutical & medical device B2B online platform, will share China’s Import and Export Market Report of Respiratory System Drugs with you.
- Source: Ddu
- 1,313
- November 17, 2017
asthma COPD Ddu College pneumonia respiratory

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.